Merged expansion US BioTek Laboratories recently merged with NutriPATH Pathology, signaling growth and an expanded service footprint in functional and integrative pathology. This creates opportunities to cross-sell comprehensive lab testing workflows, data integration, and bundled diagnostic services to a broader clinician base.

Acquisition momentum Past acquisitions of RealTime Laboratories and the merger indicate an active growth strategy. Sales teams can target acquired customer cohorts for up-sell of advanced immunology, metabolic, and specialty testing panels, while offering integrated reporting and continuous testing programs.

ELISA leadership With over 30 years of ELISA expertise and automated ELISA platforms, there is a strong value proposition for laboratories or clinics seeking high-throughput, precise immunoassay testing. Target reference labs, specialty clinics, and hospitals requiring scalable, accurate biomarker profiling.

Niche test portfolio Recent launches and expansions such as Monkeypox diagnostics, Organic Acids Profile interpretation guides, and at‑home COVID-19 testing indicate a diversified, consumer-accessible and clinician-facing portfolio. Opportunities exist to partner with telemedicine platforms, urgent care networks, and population health programs.

Global access Client base is worldwide with shipment-friendly specimens (finger stick blood, Drip N' Dry urine) and room-temperature shipping. This facilitates outbound sales to remote clinics, community health centers, and international partners, highlighting potential for managed care contracts and value-based testing arrangements.